PRESENTING COMPANIES

Acarix is a Swedish/Danish commercial stage medical device company specializing in non-invasive, acoustic rule-out of Coronary Artery Disease. The Acarix CADScor(R)System combines acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a handheld device to provide a patient specific CAD-Score in less than 10 minutes.

BONESUPPORT's three commercial-stage orthobiologic products, remodel to host bone in 6-12 mos. Two EU products locally elute antibiotics, protecting from infection. Products are compelling clinical value propositions with standout safety and efficacy in managing high cost outlier indications (trauma fractures, chronic osteomyelitis). CEO with strong commercial background driving sales growth.

Bovie Medical is a leading maker of medical devices and supplies and the developer of J-Plasma®, a patented plasma-based surgical product for cutting, coagulation and ablation that provides surgeons with greater precision. Bovie also manufactures a range of electrosurgical products and technologies, and has original equipment manufacturing agreements.

The company is a medical device start-up. First product is a portable, battery-powered ultrasound device for prehospital stroke detection, such as in ambulances. The device is safe, cost efficient ($1,000), carries wireless/Bluetooth, and is broadly applicable. Prototypes have been built, first clinical testing will start in January 2017.

C4 Imaging develops innovative medical devices based on a proprietary positive-signal MRI contrast agent (C4) developed at MD Anderson. C4 Imaging recently launched the Sirius™ MRI Marker, as an implantable medical device for use in the management of prostate cancer, and is developing a device to improve breast cancer management.

Calcivis has developed the world’s first biotech-based dental imaging system. It allows visualisation of active tooth demineralisation ‘live’, enabling a new standard of preventive care. The market opportunity for the device/consumable combination is substantial (>500m exams p.a. in US/EU). The System is CE marked and will be launched in 2017.

CMR is a high-growth medical devices business developing the next generation robotic system for minimal access surgery. The Company is post Series A, will complete cadaveric trials in 2016 and expects to close Series B in 2017 to finance commercial launch.

Deton’s Cough Collector platform enables non-invasive high-yield diagnosis of lower respiratory infections. Tens of millions of patients with lower respiratory infections often go without proper treatment because of issues related to the standard-of-care sputum samples. These samples are hard to obtain and often contaminated as they exit the patient’s mouth.

This company is dedicated to improving coronary artery investigations, for cardiologists and their patients, by developing smart devices which remove the pain points from existing procedures like FFR. Diasolve has an exciting portfolio of products to enable IC infusion and make FFR faster, more reliable and less painful for patients.

Endomag is a rapidly growing medtech headquartered in Cambridge, England with offices in Austin, Texas. Endomag has developed a unique, minimally-invasive surgical guidance platform to improve tissue localization in surgical oncology. Having delivered multi-digit European growth over the last four years, Endomag entered the US market in Summer 2016.

Fischer Imaging is developing MammoCAT™, our next generation advanced mammography and breast imaging technology and has already invested over $4.5M in its development. We plan to launch our 2D and 3D CT systems, with improved resolution and reduced dose, utliizing our proprietary slot scanning design.

GluSense is developing an injectable long-term continuous Glucose Monitor (CGM) for people with Diabetes. The CGM is miniature (0.04cc), injected under the skin in a min-invasive office procedure, and will have a lifetime of at least 1 year. Accuracy is improved comparing to competing products and minimal calibration is required.

GreenBone is the strongest bone regenerative material ever targeting severe bone damage/gaps in non-loaded and load bearing bones. Complete bone regeneration achieved in sheep critical size defect model (Israel study). Manufacturing scale up completed. Clinical development start 2Q17. Seed round 3.5M USD early 2015. Round A 8M USD planned 1Q17.

HOYA is a global med-tech company and the leading supplier of innovative high-tech and medical products. HOYA is active in the fields of healthcare and information technology providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses as well as key components for semiconductor devices, LCD panel

The May/June 2015 Journal of Infusion Nursing called short peripheral intravenous catheters an "accepted but unacceptable device" as designed now. I-V Access Technology, Inc. is a venture capital backed medical device company, which has developed the VENAGLIDE™, the next generation short peripheral intravenous catheter to address these problems.

Interface Biologics, Inc. (IBI) is a commercial stage company with core strengths in applied chemistry and material science. IBI’s technology platforms include (i) surface modification additives proven to inhibit device mediated thrombus formation and (ii) controlled local drug delivery technologies for both combination products and stand-alone pharmaceutical applications.

Kosmo Technologies has designed, patented and shown proof-of-concept for a point-of-care screening device to identify likelihood of obstructive sleep apnea. Designed for physicians and dentists to quickly screen a patient without the need for overnight studies. We are completing the design and the regulatory submission for Class II FDA approval.

MAG Optics is a London based, early stage, ophthalmic device company developing technologies relating to re-engineering human vision. Corneal inlays address presbyopia/refractive errors which impacts more than 45% of world's population. We are in proof of concept stage, transitioning to pre-clinical. We have achieved milestone of early, promising human data.

Mainstay Medical is an early commercialization stage medical device company with an innovative therapy, ReActiv8®, for people with disabling Chronic Low Back Pain who have failed conventional treatment and are not candidates for surgery. EU approval is in hand, US approval is via IDE-PMA path, now underway.

ODS Medical is developing optical instruments which identify cancerous tissue in real-time during solid tumour surgery, allowing the surgeon to find areas of tumour that previously went undetected, all within a fraction of a second. This patent protected technology has already been used in over 85 brain tumour patients.

Optina's diagnostics provide an early diagnosis of diseases through the eye. The company is completing its clinical trials for its first indication in Alzheimer. Optina gathers and analyses novel retinal information through cloud-based classification algorithm. Optina is currently generating revenue in the Academic and Pharma markets.

Portal is a clinical stage company developing a novel needle free drug delivery device for patients needing to self-inject on a regular basis because of a chronic condition. We've validated our approach clinically and are now developing druf/device combination product partnerships with global pharma companies such as Sanofi.

ProclaRx is a preclinical stage biopharmaceutical company developing a broad spectrum anti-infectives based on a novel, first in class bacterial (anti) biofilm platform technology. Its lead compounds for sinusitis and otitis media have been validated in animal models; a second approach includes woundcare products in development for a 510(k) filing.

ProLung™ is a late stage, privately funded and publicly reporting medical device company. It has developed, tested and is commercializing its non-invasive predictive analytic for the early detection of lung cancer. The ProLung device is available in Europe and is approaching US FDA approval.

Ra Medical Inc. a medical device company commercializing laser therapies for dermatology and vascular disease. For over a decade company has sold it's laser to doctors helping treat various dermatological ailments, and is is poised to launch it's novel laser catheter system for the ablation of arteria plaque via atherectomy.

Salutaris Medical Devices, Inc. is a clinical-stage company anticipating first sales revenue in 2017. We have developed a treatment for Wet AMD, a disease currently treated by chronic, expensive pharmaceuticals that only restore vision in 34%-40% of patients, leaving a large patient population with an unmet need.

seiratherm GmbH is focused on the development, production and marketing of innovative medical devices in the area of TTM (Targeted Temperature Management). Our FDA cleared devices regulate the core body temperature of critically ill or surgical patients in a rapid, safe and effective way.

Vestagen develops and markets advanced performance textile products and technologies. It enhances healthcare worker (HCW) and patient safety with VESTEX®, a new class of technology-based, patented “active barrier” protective fabrics combining antimicrobial, liquid repellent and breathability properties. VESTEX garments are designed for everyday use to protect HCWs and patients

Vigilant Biosciences is a commercially-staged company providing solutions that aid in the early detection and intervention of oral and oropharyngeal cancer. Lead 2 products are CE-registered. A LDT offering is available through our CLIA-certified lab. We expect FDA studies for our rapid, point-of-care test completed later in 2017.